(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.

The three biggest winners today are GENSIGHT BIOLOGICS, THUNDERBIRD, and NANOBIOTIX.

Financial Asset	Price	Change	Updated (EST)
GENSIGHT BIOLOGICS (SIGHT.PA)	0.95	72.73%	2023-05-08 11:50:18
THUNDERBIRD (TBIRD.AS)	0.08	53.85%	2023-05-08 11:04:56
NANOBIOTIX (NANO.PA)	6.37	48.83%	2023-05-08 11:00:35
ADOCIA (ADOC.PA)	4.12	28.75%	2023-05-08 08:39:47
SOLOCAL GROUP (LOCAL.PA)	0.15	24.83%	2023-05-08 11:03:46
CLARANOVA (CLA.PA)	2.32	11.3%	2023-05-08 11:46:26
BIOSENIC (BIOS.BR)	0.12	9.81%	2023-05-08 11:06:27
NEPI ROCKCASTLE (NRP.AS)	6.00	9.09%	2023-05-08 08:05:27
PIERRE VAC BSA ACT (VACBS.PA)	0.25	8.26%	2023-05-08 11:01:40
ACANTHE DEV. (ACAN.PA)	0.37	8.14%	2023-05-08 11:35:51

The three biggest losers today are GENTIAN DIAGNOSTIC, SODITECH, and PCI BIOTECH HOLD.

Financial Asset	Price	Change	Updated (EST)
GENTIAN DIAGNOSTIC (GENT.OL)	40.20	-15.37%	2023-05-08 11:30:09
SODITECH (SEC.PA)	1.42	-11.25%	2023-05-08 11:03:34
PCI BIOTECH HOLD (PCIB.OL)	1.85	-10.84%	2023-05-08 11:32:35
PETROLIA (PSE.OL)	3.67	-7.09%	2023-05-08 11:32:40
MEDISTIM (MEDI.OL)	273.00	-6.51%	2023-05-08 11:31:21
KEYWARE TECH. (KEYW.BR)	0.93	-6.06%	2023-05-08 08:15:48
ODFJELL SER. B (ODFB.OL)	93.80	-6.01%	2023-05-08 11:32:16
VALNEVA (VLA.PA)	5.60	-5.34%	2023-05-08 08:07:56
PAYTON PLANAR (PAY.BR)	8.30	-5.14%	2023-05-08 11:16:14
ALUMEXX N.V. (ALX.AS)	0.56	-5.08%	2023-05-08 08:00:55

Winners today

1. GENSIGHT BIOLOGICS (SIGHT.PA)

72.73% Price Change

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.

CAC 40 ended the session with GENSIGHT BIOLOGICS jumping 72.73% to €0.95 on Monday while CAC 40 rose 0.11% to €7,440.91.

Earnings Per Share

As for profitability, GENSIGHT BIOLOGICS has a trailing twelve months EPS of €-0.6.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GENSIGHT BIOLOGICS’s stock is considered to be oversold (<=20).

More news about GENSIGHT BIOLOGICS.

2. THUNDERBIRD (TBIRD.AS)

53.85% Price Change

Thunderbird Resorts, Inc., through its subsidiaries, engages in the gaming, hospitality, and real estate businesses in Nicaragua and Peru. It provides table and slot games, and sportsbooks. The company operates 3 slot parlors, 3 casinos, and 630 gaming positions. It develops, owns, and operates real estate properties; and rents office spaces. The company was formerly known as International Thunderbird Gaming Corporation and changed its name to Thunderbird Resorts, Inc. in July 2005. Thunderbird Resorts, Inc. was incorporated in 1987 and is based in Panama, the Republic of Panama.

AEX-Index ended the session with THUNDERBIRD jumping 53.85% to €0.08 on Monday, after two consecutive sessions in a row of gains. AEX-Index rose 0.29% to €752.68, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.

Volume

Today’s last reported volume for THUNDERBIRD is 153363 which is 322.41% above its average volume of 36306.

More news about THUNDERBIRD.

3. NANOBIOTIX (NANO.PA)

48.83% Price Change

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

CAC 40 ended the session with NANOBIOTIX rising 48.83% to €6.37 on Monday, following the last session’s upward trend. CAC 40 rose 0.11% to €7,440.91, following the last session’s upward trend on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, NANOBIOTIX has a trailing twelve months EPS of €-2.93.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NANOBIOTIX’s stock is considered to be oversold (<=20).

Volatility

NANOBIOTIX’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.02%, a negative 4.94%, and a positive 3.36%.

NANOBIOTIX’s highest amplitude of average volatility was 4.27% (last week), 6.79% (last month), and 3.36% (last quarter).

Moving Average

NANOBIOTIX’s worth is way above its 50-day moving average of €3.16 and way higher than its 200-day moving average of €3.65.

More news about NANOBIOTIX.

4. ADOCIA (ADOC.PA)

28.75% Price Change

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform is designed and developed to optimize the performance of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes bi-hormonal products, which include BioChaperone AsPram, which is a combination of rapid insulin aspart with pramlintide; and BioChaperone Glargine Liraglutidea, which is a fixed combination of insulin glargine with an analogue of the GLP-1 receptor. In addition, the company's preclinical pipeline includes multihormonal products for the treatment of obesity, including BioChaperone GluExe, which is a combination of glucagon and exenatide; PramExe, which is a combination of pramlintide and exenatide; and BioChaperone PramGluExe, which is a triple combination of pramlintide, glucagon and exenatide. It has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. The company was incorporated in 2005 and is headquartered in Lyon, France.

CAC 40 ended the session with ADOCIA jumping 28.75% to €4.12 on Monday, after three successive sessions in a row of gains. CAC 40 jumped 0.11% to €7,440.91, following the last session’s upward trend on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, ADOCIA has a trailing twelve months EPS of €-1.22.

Revenue Growth

Year-on-year quarterly revenue growth grew by 312.1%, now sitting on 13.95M for the twelve trailing months.

More news about ADOCIA.

5. SOLOCAL GROUP (LOCAL.PA)

24.83% Price Change

Solocal Group S.A. provides digital services in France and internationally. Its services include connect that allows VSEs and SMEs to manage their digital presence on PagesJaunes and various Web through mobile application, or a web interface, as well as manages interactions between professionals and their customers; and booster that allows companies to increase their digital visibility in the Web. The company was formerly known as PagesJaunes Groupe and changed its name to SoLocal Group S.A. in June 2013. Solocal Group S.A. was founded in 1896 and is based in Boulogne-Billancourt, France.

CAC 40 ended the session with SOLOCAL GROUP rising 24.83% to €0.15 on Monday, after five consecutive sessions in a row of losses. CAC 40 jumped 0.11% to €7,440.91, following the last session’s upward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, SOLOCAL GROUP has a trailing twelve months EPS of €0.1.

PE Ratio

SOLOCAL GROUP has a trailing twelve months price to earnings ratio of 1.49. Meaning, the purchaser of the share is investing €1.49 for every euro of annual earnings.

Moving Average

SOLOCAL GROUP’s worth is way below its 50-day moving average of €0.52 and way under its 200-day moving average of €0.74.

Revenue Growth

Year-on-year quarterly revenue growth declined by 6.2%, now sitting on 414.64M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SOLOCAL GROUP’s stock is considered to be overbought (>=80).

Yearly Top and Bottom Value

SOLOCAL GROUP’s stock is valued at €0.15 at 22:40 EST, way under its 52-week low of €0.41.

More news about SOLOCAL GROUP.

6. CLARANOVA (CLA.PA)

11.3% Price Change

Claranova SE, a technology company, engages in personalized e-commerce, software publishing, and internet of things businesses in the United States, the United Kingdom, Germany, France, other European countries, and internationally. It operates through three segments: PlanetArt, Avanquest, and myDevices. The PlanetArt segment offers FreePrints Photobooks; FreePrints photo tiles for wall decorations; FreePrints cards; FreePrints gifts and Personal Creations for personalized gifts; SimplytoImpress; and CafePress and Gifts.com websites. The Avanquest segment provides the antivirus, ad blocker, cleaning, and optimization tools sold under the Adaware brand; document management tools under the SodaPDF brand name; and photo editor software and apps under the inPixio brand. The myDevices segment offers myDevices, an application platform that provides a range of IoT solutions for the management of assets. It also provides SignPDF, a new digital signature solution. The company was formerly known as Avanquest S.A. and changed its name to Claranova S.E. in June 2017. Claranova SE was incorporated in 1984 and is headquartered in La Garenne-Colombes, France.

CAC 40 ended the session with CLARANOVA rising 11.3% to €2.32 on Monday, after five successive sessions in a row of gains. CAC 40 jumped 0.11% to €7,440.91, following the last session’s upward trend on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, CLARANOVA has a trailing twelve months EPS of €-0.42.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -143.31%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 12.5%, now sitting on 508.5M for the twelve trailing months.

Volatility

CLARANOVA’s last week, last month’s, and last quarter’s current intraday variation average was 0.93%, 0.17%, and 2.03%.

CLARANOVA’s highest amplitude of average volatility was 0.93% (last week), 1.27% (last month), and 2.03% (last quarter).

Yearly Top and Bottom Value

CLARANOVA’s stock is valued at €2.32 at 22:40 EST, way under its 52-week high of €4.03 and way above its 52-week low of €1.82.

Volume

Today’s last reported volume for CLARANOVA is 382158 which is 232.35% above its average volume of 114986.

More news about CLARANOVA.

7. BIOSENIC (BIOS.BR)

9.81% Price Change

BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures. The company is based in Mont-Saint-Guibert, Belgium.

BEL 20 ended the session with BIOSENIC rising 9.81% to €0.12 on Monday while BEL 20 rose 0.16% to €3,805.96.

Earnings Per Share

As for profitability, BIOSENIC has a trailing twelve months EPS of €-0.38.

Volume

Today’s last reported volume for BIOSENIC is 58602 which is 82.01% below its average volume of 325829.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BIOSENIC’s stock is considered to be oversold (<=20).

More news about BIOSENIC.

8. NEPI ROCKCASTLE (NRP.AS)

9.09% Price Change

NEPI Rockcastle is the premier owner and operator of shopping centres in Central and Eastern Europe (CEE), with presence in nine countries and an investment portfolio of €5.8 billion as at 31 December 2021. The Group benefits from a highly-skilled internal management team which combines asset management, development, investment, leasing and financial expertise. Geographically diverse management skills allow NEPI Rockcastle to pursue CEE property opportunities efficiently, benefiting from a strategic advantage in the acquisition, development and management of properties. NEPI Rockcastle owns and operates 52 retail properties (excluding joint venture) which attracted 244 million visits in 2021 (325 million visits in 2019). With group-level management of tenant relationships and a focus on cross-country collaboration, the Group is the leading strategic partner for major retailers targeting CEE countries. The Group's financial strategy includes maintaining a profile of adequate liquidity, conservative gearing, and a diverse debt structure, which combines secured and unsecured bank debt with unsecured bonds listed on the Irish Stock Exchange. NEPI Rockcastle is investment-grade rated by Standard & Poor's (BBB, stable outlook) and Fitch (BBB, positive outlook). NEPI Rockcastle's shares are listed on the Johannesburg Stock Exchange (“JSE”), Euronext Amsterdam (“Euronext”) and A2X. The Group voluntarily distributes at least 90% of its distributable earnings on a semi-annual basis.

AEX-Index ended the session with NEPI ROCKCASTLE rising 9.09% to €6.00 on Monday while AEX-Index jumped 0.29% to €752.68.

Earnings Per Share

As for profitability, NEPI ROCKCASTLE has a trailing twelve months EPS of €0.72.

PE Ratio

NEPI ROCKCASTLE has a trailing twelve months price to earnings ratio of 8.33. Meaning, the purchaser of the share is investing €8.33 for every euro of annual earnings.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NEPI ROCKCASTLE’s stock is considered to be oversold (<=20).

Volatility

NEPI ROCKCASTLE’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.96%, a negative 0.01%, and a positive 5.50%.

NEPI ROCKCASTLE’s highest amplitude of average volatility was 6.73% (last week), 5.48% (last month), and 5.50% (last quarter).

More news about NEPI ROCKCASTLE.

9. PIERRE VAC BSA ACT (VACBS.PA)

8.26% Price Change

CAC 40 ended the session with PIERRE VAC BSA ACT rising 8.26% to €0.25 on Monday while CAC 40 rose 0.11% to €7,440.91.

Yearly Top and Bottom Value

PIERRE VAC BSA ACT’s stock is valued at €0.25 at 22:40 EST, higher than its 52-week high of €0.24.

More news about PIERRE VAC BSA ACT.

10. ACANTHE DEV. (ACAN.PA)

8.14% Price Change

Acanthe owns a property portfolio mainly located in the Central Business District of Paris. Its portfolio represents a total area of 12 645 m², consists of 7 buildings. 95,2% in value in the Central Business District and the historic center of Paris, the portfolio consists mainly of offices that provide regular and high profitability in an area where demand is high.The strategy pursued by Acanthe aims to offer its shareholders a high return and secure thanks to the quality of its portfolio and its policy of continuous cost control.

CAC 40 ended the session with ACANTHE DEV. jumping 8.14% to €0.37 on Monday while CAC 40 rose 0.11% to €7,440.91.

Earnings Per Share

As for profitability, ACANTHE DEV. has a trailing twelve months EPS of €0.03.

PE Ratio

ACANTHE DEV. has a trailing twelve months price to earnings ratio of 12.4. Meaning, the purchaser of the share is investing €12.4 for every euro of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.2%.

Volatility

ACANTHE DEV.’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.46%, a negative 1.15%, and a positive 2.70%.

ACANTHE DEV.’s highest amplitude of average volatility was 2.55% (last week), 2.45% (last month), and 2.70% (last quarter).

More news about ACANTHE DEV..

Losers Today

1. GENTIAN DIAGNOSTIC (GENT.OL)

-15.37% Price Change

Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research in Europe, Asia, and the United States. It offers in-vitro diagnostic reagents for clinical chemistry analyzers. The company's products include the gentian calprotectin immunoassay, a turbidimetric immunoassay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Cystatin C, a superior GFR marker for the diagnosis and therapeutic control of renal function; NT-proBNP Immunoassay for diagnosis, monitoring, and assessment of severity in individuals suspected of having congestive heart failure; and Canine c-reactive protein (CRP) immunoassay, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine CRP in dog plasma and serum. It also provides turbidimetric SARS-CoV-2 total antibody immunoassay, a quantitative antibody test for detecting antibodies targeting the S1-subunit. Gentian Diagnostics ASA was incorporated in 2001 and is headquartered in Moss, Norway.

Oslo Børs Benchmark Index_GI ended the session with GENTIAN DIAGNOSTIC sliding 15.37% to €40.20 on Monday, following the last session’s downward trend. Oslo Børs Benchmark Index_GI rose 0.71% to €1,213.09, following the last session’s upward trend on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, GENTIAN DIAGNOSTIC has a trailing twelve months EPS of kr-1.55.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -14.36%.

Volume

Today’s last reported volume for GENTIAN DIAGNOSTIC is 123 which is 98.68% below its average volume of 9380.

Moving Average

GENTIAN DIAGNOSTIC’s worth is under its 50-day moving average of kr40.47 and under its 200-day moving average of kr40.77.

More news about GENTIAN DIAGNOSTIC.

2. SODITECH (SEC.PA)

-11.25% Price Change

Soditech SA engages in the integration of mechanical, thermal, and electronic sub-assemblies in space, research, and defense fields in France. It designs structural sub-assemblies and integrates optical and thermal equipment, such as OSRs, SSMs, heaters, and heat pipes; designs and manufactures multi-layer insulation products; and designs, manufactures, and tests space harnesses on instruments or platforms. The company also provides calculation services, such as static, dynamic, thermal, and thermoelastic; designs assembly tools; and designs and produces super insulating multi-layer mattresses for ultra-vacuum areas. In addition, it develops, qualifies, manufactures, and tests embedded cabinets; and designs, assembles, and tests racks and test equipment racks. The company was formerly known as Soditech Ingenierie SA. Soditech SA was founded in 1990 and is headquartered in Aix-en-Provence, France.

CAC 40 ended the session with SODITECH sliding 11.25% to €1.42 on Monday, following the last session’s upward trend. CAC 40 jumped 0.11% to €7,440.91, following the last session’s upward trend on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, SODITECH has a trailing twelve months EPS of €0.37.

PE Ratio

SODITECH has a trailing twelve months price to earnings ratio of 3.84. Meaning, the purchaser of the share is investing €3.84 for every euro of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.54%.

Volatility

SODITECH’s last week, last month’s, and last quarter’s current intraday variation average was a positive 2.22%, a negative 0.52%, and a positive 8.09%.

SODITECH’s highest amplitude of average volatility was 6.67% (last week), 9.07% (last month), and 8.09% (last quarter).

Moving Average

SODITECH’s value is under its 50-day moving average of €1.56 and below its 200-day moving average of €1.49.

Volume

Today’s last reported volume for SODITECH is 300 which is 53.63% below its average volume of 647.

Revenue Growth

Year-on-year quarterly revenue growth declined by 12.7%, now sitting on 4.59M for the twelve trailing months.

More news about SODITECH.

3. PCI BIOTECH HOLD (PCIB.OL)

-10.84% Price Change

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in Phase I clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Bavarian Nordic, BioNTech, Phio Pharmaceuticals, DCprime, eTheRNA immunotherapies, IMV, and Aposense. PCI Biotech Holding ASA is based in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with PCI BIOTECH HOLD sliding 10.84% to €1.85 on Monday, following the last session’s downward trend. Oslo Børs Benchmark Index_GI rose 0.71% to €1,213.09, following the last session’s upward trend on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, PCI BIOTECH HOLD has a trailing twelve months EPS of kr-1.54.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -64.36%.

Volume

Today’s last reported volume for PCI BIOTECH HOLD is 179664 which is 34.84% above its average volume of 133238.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, PCI BIOTECH HOLD’s stock is considered to be oversold (<=20).

Moving Average

PCI BIOTECH HOLD’s value is way below its 50-day moving average of kr2.08 and way under its 200-day moving average of kr2.38.

Volatility

PCI BIOTECH HOLD’s last week, last month’s, and last quarter’s current intraday variation average was 0.97%, 0.37%, and 3.77%.

PCI BIOTECH HOLD’s highest amplitude of average volatility was 4.64% (last week), 3.17% (last month), and 3.77% (last quarter).

More news about PCI BIOTECH HOLD.

4. PETROLIA (PSE.OL)

-7.09% Price Change

Petrolia SE, together with its subsidiaries, sells and rents energy service equipment to energy industry in Norway, rest of Europe, Asia, and Australia. It operates through two segments, Energy and Energy Service. The company engages in the exploration and production of oil and gas, as well as produces hydrogen and ammonia. It also offers drill pipes, test strings and tubing, and other equipment, as well as casing, handling, and auxiliary tools; and equipment inspection and maintenance services. In addition, the company offers casing and tubing running, drilling, and make and brake services. It serves energy companies, drilling contractors, and energy service companies. The company was formerly known as Petrolia E&P Holdings SE and changed its name to Petrolia SE in January 2013. Petrolia SE was founded in 1997 and is based in Limassol, Cyprus.

Oslo Børs Benchmark Index_GI ended the session with PETROLIA sliding 7.09% to €3.67 on Monday while Oslo Børs Benchmark Index_GI rose 0.71% to €1,213.09.

Earnings Per Share

As for profitability, PETROLIA has a trailing twelve months EPS of kr-0.56.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1.9%.

Volatility

PETROLIA’s last week, last month’s, and last quarter’s current intraday variation average was 0.98%, 0.05%, and 3.04%.

PETROLIA’s highest amplitude of average volatility was 3.46% (last week), 2.88% (last month), and 3.04% (last quarter).

Moving Average

PETROLIA’s worth is below its 50-day moving average of kr4.05 and way below its 200-day moving average of kr4.62.

Yearly Top and Bottom Value

PETROLIA’s stock is valued at kr3.67 at 22:40 EST, way under its 52-week high of kr9.50 and higher than its 52-week low of kr3.57.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, PETROLIA’s stock is considered to be oversold (<=20).

More news about PETROLIA.

5. MEDISTIM (MEDI.OL)

-6.51% Price Change

Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with MEDISTIM dropping 6.51% to €273.00 on Monday, after three consecutive sessions in a row of gains. Oslo Børs Benchmark Index_GI jumped 0.71% to €1,213.09, following the last session’s upward trend on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, MEDISTIM has a trailing twelve months EPS of kr6.34.

PE Ratio

MEDISTIM has a trailing twelve months price to earnings ratio of 43.06. Meaning, the purchaser of the share is investing kr43.06 for every norwegian krone of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.89%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MEDISTIM’s stock is considered to be oversold (<=20).

Earnings Before Interest, Taxes, Depreciation, and Amortization

MEDISTIM’s EBITDA is 8.9.

Moving Average

MEDISTIM’s value is above its 50-day moving average of kr257.46 and way higher than its 200-day moving average of kr242.49.

Revenue Growth

Year-on-year quarterly revenue growth grew by 11.3%, now sitting on 499.39M for the twelve trailing months.

More news about MEDISTIM.

6. KEYWARE TECH. (KEYW.BR)

-6.06% Price Change

Keyware Technologies NV, an independent fintech company, provides electronic payment solutions in Belgium. It offers payment transaction software for banks and financial institutions, tokenization software, instalment payment solutions, and ordering and payment app software; and payment processing and management services, as well as engages in the rental and sale of payment terminals. The company was incorporated in 1996 and is headquartered in Zaventem, Belgium.

BEL 20 ended the session with KEYWARE TECH. falling 6.06% to €0.93 on Monday, following the last session’s upward trend. BEL 20 rose 0.16% to €3,805.96, following the last session’s upward trend on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, KEYWARE TECH. has a trailing twelve months EPS of €0.05.

PE Ratio

KEYWARE TECH. has a trailing twelve months price to earnings ratio of 18.6. Meaning, the purchaser of the share is investing €18.6 for every euro of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 2.37%.

More news about KEYWARE TECH..

7. ODFJELL SER. B (ODFB.OL)

-6.01% Price Change

Odfjell SE engages in the transportation and storage of bulk liquid chemicals, acids, edible oils, and other special products. The company operates Chemical Tankers and Tank Terminals segments. It owns and operates chemical tankers that offers global and regional transportation; and tank terminals, which provides storage of various chemical and petroleum products. As of December 31, 2022, it operated a chemical tanker fleet of 69 vessels, including 46 owned, 6 bareboat chartered, 14 time chartered vessels, and 3 pool vessels. The company's terminal network comprises of 450 tanks with 1.2 million cubic meters of storage capacity. It operates in Norway, the Netherlands, rest of Europe, North America, South America, the Middle East, Asia, Australasia, and Africa. Odfjell SE was founded in 1914 and is headquartered in Bergen, Norway.

Oslo Børs Benchmark Index_GI ended the session with ODFJELL SER. B dropping 6.01% to €93.80 on Monday, following the last session’s downward trend. Oslo Børs Benchmark Index_GI rose 0.71% to €1,213.09, following the last session’s upward trend on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, ODFJELL SER. B has a trailing twelve months EPS of kr19.27.

PE Ratio

ODFJELL SER. B has a trailing twelve months price to earnings ratio of 4.87. Meaning, the purchaser of the share is investing kr4.87 for every norwegian krone of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.73%.

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on Feb 13, 2023, the estimated forward annual dividend rate is 9.37 and the estimated forward annual dividend yield is 9.6%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 12.4%, now sitting on 1.31B for the twelve trailing months.

Earnings Before Interest, Taxes, Depreciation, and Amortization

ODFJELL SER. B’s EBITDA is 152.78.

Yearly Top and Bottom Value

ODFJELL SER. B’s stock is valued at kr93.80 at 22:40 EST, way below its 52-week high of kr105.00 and way higher than its 52-week low of kr42.80.

More news about ODFJELL SER. B.

8. VALNEVA (VLA.PA)

-5.34% Price Change

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

CAC 40 ended the session with VALNEVA falling 5.34% to €5.60 on Monday while CAC 40 rose 0.11% to €7,440.91.

Earnings Per Share

As for profitability, VALNEVA has a trailing twelve months EPS of €-1.67.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, VALNEVA’s stock is considered to be oversold (<=20).

More news about VALNEVA.

9. PAYTON PLANAR (PAY.BR)

-5.14% Price Change

Payton Planar Magnetics Ltd., together with its subsidiaries, engages in development, manufacture, and marketing of planar and conventional transformers worldwide. It provides various planar transformers; inductors, including common mode chocks; and off the shelf SMT planar transformers. The company also supplies planar magnetic components. It serves telecom/datacenter, automotive companies, and industrial companies. The company was incorporated in 1992 and is based in Ness-Ziona, Israel. Payton Planar Magnetics Ltd. is a subsidiary of Payton Industries Ltd.

BEL 20 ended the session with PAYTON PLANAR sliding 5.14% to €8.30 on Monday, after two successive sessions in a row of gains. BEL 20 rose 0.16% to €3,805.96, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, PAYTON PLANAR has a trailing twelve months EPS of €0.72.

PE Ratio

PAYTON PLANAR has a trailing twelve months price to earnings ratio of 11.53. Meaning, the purchaser of the share is investing €11.53 for every euro of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.29%.

Moving Average

PAYTON PLANAR’s worth is under its 50-day moving average of €9.03 and way below its 200-day moving average of €9.29.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, PAYTON PLANAR’s stock is considered to be oversold (<=20).

Yearly Top and Bottom Value

PAYTON PLANAR’s stock is valued at €8.30 at 22:40 EST, way below its 52-week high of €10.40 and way higher than its 52-week low of €7.50.

More news about PAYTON PLANAR.

10. ALUMEXX N.V. (ALX.AS)

-5.08% Price Change

Alumexx N.V. manufactures and sells scaffoldings, stairs, ladders, accessories, and tools for indoor or outdoor use in the Netherlands and internationally. The company was formerly known as Phelix N.V. and changed its name to Alumexx N.V. in January 2018. Alumexx N.V. was founded in 1991 and is based in Etten-Leur, the Netherlands.

AEX-Index ended the session with ALUMEXX N.V. falling 5.08% to €0.56 on Monday while AEX-Index rose 0.29% to €752.68.

Earnings Per Share

As for profitability, ALUMEXX N.V. has a trailing twelve months EPS of €0.01.

PE Ratio

ALUMEXX N.V. has a trailing twelve months price to earnings ratio of 56. Meaning, the purchaser of the share is investing €56 for every euro of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.5%.

More news about ALUMEXX N.V..

Stay up to date with our winners and losers daily report